Changes of immunological parameters reflect quality of life-related toxicity during chemotherapy in patients with advanced colorectal cancer

Anticancer Research

Volumn 28, Issue 1 B, 2008, Pages 373-378

  Yoshimatsu, Kazuhiko ^a   Kuhara, Kotaro ^a   Itagaki, Hiroko ^a   Aizawa, Masaki ^a   Yokomizo, Hajime ^a   Fujimoto, Takashi ^a   Otani, Taisuke ^a   Osawa, Gakuji ^a   Kobayashi, R I E ^a   Ogawa, Kenji ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

CD4+CD25+ T cell; Colorectal cancer; Host immunity; Low dose chemotherapy; Soluble IL 2R

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; FLUOROURACIL; FOLINIC ACID; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; IRINOTECAN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CD4+ CD25+ T LYMPHOCYTE; CELL ISOLATION; CLINICAL ARTICLE; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DIARRHEA; FATIGUE; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNITY; MALE; NAUSEA; PHENOTYPE; PRIORITY JOURNAL; QUALITY OF LIFE; STOMATITIS; TREATMENT OUTCOME; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CD4-CD8 RATIO; COLORECTAL NEOPLASMS; CYTOKINES; DRUG COMBINATIONS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NEOPLASM STAGING; OXONIC ACID; QUALITY OF LIFE; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES; TEGAFUR;

EID: 40549091272     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL and Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. New Engl J Med 343: 905-914, 2000.
2. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L and Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. LANCET 355: 1041-1047, 2000.
3. Delaunoit T, Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Findlay BP, Thomas SP, Salim M, Schaefer PL, Stella PJ, Green E and Mailliard JA: Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741. Cancer 101: 2170-2176, 2004.
4. NCCN Practice Guidelines on Oncology-v.2.2007. Colon Cancer Chemotherapy for advanced or metastatic disease. http://www.nccn.org/professionals/ physician_gls/PDF/colon.pdf
5. Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF and Kabbinavar F: Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23: 3502-3508, 2005.
6. Lecomte T, Ferraz JM, Zinzindohoué F, Loriot MA, Tregouet DA, Landi B, Berger A, Cugnenc PH, Jian R, Beaune P and Laurent-Puig P: Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 10: 5880-5888, 2004.
7. Cho HJ, Park YS, Kang WK, Kim JW and Lee SY: Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity. Ther Drug Monit 29: 190-196, 2007.
8. Côté JF, Kirzin S, Kramar A, Mosnier JF, Diebold MD, Soubeyran I, Thirouard AS, Selves J, Laurent-Puig P and Ychou M: UGT1A1 Polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 13: 3269-3275, 2007.
9. Rouits E, Boisdron-Celle M, Dumont A, Guérin O, Morel A and Gamelin E: Rele-vance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res 10: 5151-5159, 2004.
10. Massacesi C, Terrazzino S, Marcucci F, Rocchi MB, Lippe P, Bisonni R, Lombardo M, Pilone A, Mattioli R and Leon A: Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer 106: 1007-1016, 2006.
11. World Health Organization: WHO handbook for reporting results of cancer treatment. WHO Offset publication no. 48, Geneva, 1979.
12. Yoshimatsu K, Yokomizo H, Fujimoto T, Umehara A, Otani T, Matsumoto A, Osawa G, Shiozawa S, Katsube T, Naritaka Y and Ogawa K: Low-dose chemotherapy is practically useful for the patients with intrapelvic recurrence of rectal cancer. Anticancer Res 27: 1635-1640, 2007.
13. Yoshimatsu K, Yokomizo H, Fujimoto T, Umehara A, Otani T, Matsumoto A, Osawa G, Shiozawa S, Katsube T, Naritaka Y and Ogawa K: First-line chemotherapy with low-dose leucovorin plus 5-fluorouracil (LV/5-FU) for elderly patients with metastatic colorectal cancer. Anticancer Res 27: 1641-1644, 2007.
14. Yoshimatsu K, Yokomizo H, Fujimoto T, Umehara A, Otani T, Matsumoto A Osawa G and Ogawa K: Pilot study of simplified low-dose S-1 plus CPT-11 as first-line chemotherapy for patients with advanced colorectal cancer. Anticancer Res 27: 1657-1662, 2007.
15. Kobayashi R, Yoshimatsu K, Yokomizo H, Katsube T and Ogawa K: Low-dose chemotherapy with leucovorin plus 5-fluorouracil for colorectal cancer can maintain host immunity. Anticancer Res 27: 675-680, 2007.
16. Pui CH, Ip SH, Kung P, Dodge RK, Berard CW, Crist WM and Murphy SB: High serum interleukin-2 receptor levels are related to advanced disease and a poor outcome in childhood non-Hodgkin's lymphoma. Blood 70: 624-628, 1987.
17. Barak V, Ginzburg M, Kalickman I and Polliack A: Serum soluble interleukin-2 receptor levels are associated with clinical disease status and histopathological grade in non-Hodgkin's lymphoma and chronic lymphatic leukemia. Leuk Lymphoma 7: 431-438, 1992.
18. Stasi R, Zinzani PL, Galieni P, Lauta VM, Damasio E, Dispensa E, Dammacco F, Papa G and Tura S: Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma. Br J Haematol 88: 770-777, 1988.
19. Steis RG, Marcon L, Clark J, Urba W, Longo DL, Nelson DL and Maluish AE: Se-rum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia. Blood 71: 1304-1309, 1988.
20. Motoi T, Uchiyama T, Uchini H, Ueda R and Araki K: Serum soluble interleukin-2 receptor levels in patients with adult T-cell leukemia and human T-cell leuke-mia/lymphoma virus type-I seropositive healthy carriers. Jpn J Cancer Res 79: 593-599, 1988.
21. Ishida H, Kumagai S, Umehara H, Sano H, Tagaya Y, Yodoi J and Imura H: Im-paired expression of high affinity interleukin-2 receptor on activated lymphocytes from patients with systemic lupus erythematosus. J Immunol 139: 1070-1074, 1987.
22. Rubin LA and Nelson DL: The soluble interleukin-2 recptor: biology, function, and clinical application. Ann Intern Med 11: 619-627, 1990.
23. Naumanik W and Chyczewska E: The clinical significance of serum soluble inter-leukin-2 recepter (sIL-2R) concentration in lung cancer. Folia Histochem Cytobiol 39: 185-186, 2001.
24. Naumanik W, Chyczewska E, Kovalchuk O, Talalaj J, Izycki T and Panek B: Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer. Ann Acd Med Bialost 49: 246-251, 2004.
25. Shibata M, Nezu T, Kanou H, Nagata Y, Kimura T, Takekawa M, Ando K and Fukuzawa M: Immunomuduratory effects of low dose cis-diaminedichloroplatinum (cisplatin) combined with UFT and PSK in patients with advanced colorectal cancer. Cancer Invest 20: 166-173, 2002.
26. Vuoristo MS, Laine S, Huhtala H, Parvinen LM, Hahka-Kemppinen M, Korpela M, Kumpulainen E and Kellokumpu-Lehtinen P: Serum adhesion molecules and inter-leukin-2 receptor as markers of tumour load and prognosis in advanced cutaneous melanoma. Eur J Cancer 37: 1629-1634, 2001.
27. Soker M, Colpan L, Ece A, Devecioglu C and Haspolat K: Serum levels of IL-1 beta, sIL-2R, IL-6, IL-8, amd TNF-alpha in febrile children with cancer and neutropenia. Med Oncol 18: 51-57, 2001.
28. Shibata M and Takekawa M: Increased serum concentration of circulating soluble receptor for interleukin-2 and its effect as a prognostic indicator in cachectic patients with gastric and colorectal cancer. Oncology 56: 54-58, 1999.
29. Rovelli F, Lissoni P, Crispino S, Barni S, Fumagalli G, Paolorossi F and Tancini G: Increased levels of soluble interleukin-2 receptor in advanced solid tumors: a preliminary study. Tumori 74: 633-637, 1988.
30. Skog ALH, Wersall P, Ragnhammar P, Frodin JE and Mellstedt H: Treatment with GM-CSF and IL-2 in patients with metastatic colorectal carcinoma induced high serum levels of neopterin ans sIL-2R, an indicator of immune suppression. Cancer Immunol Immunother 51: 255-262, 2002.
31. Sakaguchi S, Sakaguchi N, Asano M, Itoh M and Toda M: Immunologic self-tolerance maintained by activated T-cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of single mechanism of self-tolerance causes various autoimmune disease. J Immunol 155: 1151-1164, 1995.
32. Asano M, Toda M, Sakaguchi N and Sakaguchi S: Autoimmune disease as a consequence of developmental abnormality of T-cell subpopulation. J Exp Med 184: 387-396, 1996.
33. + regulatory T-cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22: 531-562, 2004.
34. + regulatory T-cells in immunological tolerance to self and non-self. Nat Immunol 6: 345-352, 2005.
35. Mills KH and McGuirk P: Antigen-specific regulatory T-cells; their induction and role in infection. Semin Immunol 16: 107-117, 2004.
36. Vigouroux S, Yvon E, Biagi E and Brenner MK: Antigen-induced regulatory T-cells. Blood 104: 26-33, 2004.
37. + regulatory T-cells in patients with gastrointestinal malignancies: possible involvement of regulatory T-cells in disease progression. Cancer 98: 1089-1099, 2003.
38. Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H and Fujii H: Increased populations of regulatory T-cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 9: 4404-4408, 2003.
39. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L and Zou W: Specific recruitment of regulatory T-cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942-949, 2004.
40. Mukherji B, Chakraborty NG and Sivanandham M: T-cell clones that react against autologous human tumors. Immunol Rev 116: 33-62, 1990.
41. Snyder JT, Alexander-Miller MA, Berzofskyl JA and Belyakov IM: Molecular mechanisms and biological significance of CTL avidity. Curr HIV Res 1: 287-294, 2003.